1L HER2- GC/GEJC PFS and ORR

Improved additional efficacy outcomes in patients with 1L HER2- GC/GEJC and PD-L1 scores ≥1% vs placebo + chemotherapy1,2

Additional efficacy outcomes in 1L HER2- GC/GEJC: PFS, ORR, and DoR with PD-L1 ≥1%

6.9 months mPFS with TEVIMBRA + chemotherapy vs 5.9 months with placebo + chemotherapy; HR: 0.78 (95% CI: 0.67-0.91)1

1L_GC_Km_Curve_R3 RGB_DESKTOP
1L_GC_Km_Curve_R3 RGB_MOBILE

This retrospective subgroup analysis included patients with a PD-L1 score ≥1% only. Estimated using the Kaplan-Meier method.

Image description

Additional efficacy outcomes:

Among patients with a PD-L1 score ≥1%,

  • At 3 years (36 months), TEVIMBRA + chemotherapy (n=432) had a 15.2% median progression-free survival rate (95% CI: 11.6-19.3) vs 7.4% (95% CI: 4.5-10.2) with placebo + chemotherapy (n=453)
  • At 2 years (24 months), TEVIMBRA + chemotherapy (n=432) had a 17.1% median progression-free survival rate (95% CI: 13.3-21.2) vs 9.1% (95% CI: 6.4-12.4) with placebo + chemotherapy (n=453)
  • At 1 year (12 months), TEVIMBRA + chemotherapy (n=432) had a 30.3% median progression-free survival rate (95% CI: 25.7-35.0) vs 20.7% (95% CI: 16.8-24.9) with placebo + chemotherapy (n=453)

6.9 months mPFS with TEVIMBRA + chemotherapy vs 5.9 months mPFS with placebo + chemotherapy; HR: 0.78 (95% CI: 0.67-0.91).

Improved response rates (additional efficacy outcomes)1

  • Nearly half of patients responded to TEVIMBRA + chemotherapy: 48% ORR (95% CI: 43%-53%) vs 41% ORR with placebo + chemotherapy (95% CI: 37%-46%)
  • mDoR of 8.6 months with TEVIMBRA + chemotherapy (95% CI: 7.8-10.4) vs 7.2 months with placebo + chemotherapy (95% CI: 5.8-8.3)

Frequently Asked Questions

Expand All

TEVIMBRA + chemotherapy reported extended median progression-free survival* of 6.9 months vs 5.9 months with placebo + chemotherapy. The PFS rate at 3 years was 15.2% with TEVIMBRA + chemotherapy vs 7.4% with placebo + chemotherapy.1,2

 

This retrospective subgroup analysis included patients with a PD-L1 score ≥1% only. Estimated using the Kaplan-Meier method.

*PFS was an additional efficacy outcome in this trial.1

Nearly half of patients responded to TEVIMBRA + chemotherapy: 48% ORR* (95% CI: 43%-53%) vs 41% ORR* with placebo + chemotherapy (95% CI: 37%-46%).1

*ORR was an additional efficacy outcome in this trial.1

View safety in 1L HER2- GC/GEJC
1L, first line; CPS, combined positive score; DCR, disease control rate; GC, gastric cancer; GEJC, gastroesophageal junction cancer; HR, hazard ratio; mDoR, median duration of response; mPFS, median progression-free survival; ORR, overall response rate; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free survival.

References: 1. TEVIMBRA. Prescribing Information. BeOne Medicines USA, Inc.; 2026. 2. Moehler M, Oh DY, Kato K, et al. Adv Ther. 2025;42(5):2248-2268. doi:10.1007/s12325-025-03133-7

You are being redirected to nccn.org

Continue
Cancel
This site is intended for US healthcare professionals only. Please confirm you are a US healthcare professional.
test
Visit the patient site

You are being redirected to myBeOneSupport.com

Continue
Cancel